Published in PLoS One on November 04, 2013
Deciphering cancer heterogeneity: the biological space. Front Cell Dev Biol (2014) 0.77
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res (2010) 25.85
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04
Missing value estimation methods for DNA microarrays. Bioinformatics (2001) 20.84
Computational systems biology. Nature (2002) 10.33
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
The microcosmos of cancer. Nature (2012) 4.50
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics (2009) 2.02
MicroRNAs in liver disease. Gastroenterology (2012) 1.76
Discovery of microRNA-mRNA modules via population-based probabilistic learning. Bioinformatics (2007) 1.70
microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol (2010) 1.69
A novel computational framework for simultaneous integration of multiple types of genomic data to identify microRNA-gene regulatory modules. Bioinformatics (2011) 1.68
Prediction of regulatory modules comprising microRNAs and target genes. Bioinformatics (2005) 1.55
Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open (2012) 1.50
Finding microRNA regulatory modules in human genome using rule induction. BMC Bioinformatics (2008) 1.32
Systems biology at the Institute for Systems Biology. Brief Funct Genomic Proteomic (2008) 1.30
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology (2010) 1.28
Exploring complex miRNA-mRNA interactions with Bayesian networks by splitting-averaging strategy. BMC Bioinformatics (2009) 1.13
Advanced computing for systems biology. Brief Bioinform (2006) 1.00
Graph classification by means of Lipschitz embedding. IEEE Trans Syst Man Cybern B Cybern (2009) 0.78
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell (2011) 2.73
Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res (2007) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol (2005) 2.15
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
The role of cytokines in hepatocellular carcinoma. J Leukoc Biol (2006) 1.75
Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res (2007) 1.73
Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology (2013) 1.73
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology (2013) 1.63
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol (2012) 1.46
Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology (2004) 1.41
Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol (2010) 1.41
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
Nucleophosmin and human cancer. Cancer Detect Prev (2006) 1.29
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology (2010) 1.28
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther (2009) 1.23
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem (2002) 1.22
Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis (2003) 1.13
Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res (2013) 1.09
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer (2010) 1.05
A Yin-Yang balancing act of the lin28/let-7 link in tumorigenesis. J Hepatol (2010) 1.03
SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. FASEB J (2002) 1.01
Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer (2010) 1.00
Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res (2010) 0.99
microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer (2012) 0.97
Mechanisms of inactivation of hepatitis a virus by chlorine. Appl Environ Microbiol (2002) 0.92
Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology (2014) 0.91
Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes. Mol Med (2006) 0.90
Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology (2015) 0.89
Translating the metastasis paradigm from scientific theory to clinical oncology. Clin Cancer Res (2009) 0.89
Future of molecular profiling of human hepatocellular carcinoma. Future Oncol (2007) 0.89
Mechanisms of inactivation of hepatitis A virus in water by chlorine dioxide. Water Res (2004) 0.88
Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses. J Immunol (2012) 0.87
Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. Hepatology (2014) 0.83
Power play: scoring our goals for liver cancer with better GWAS study design. J Hepatol (2010) 0.82
microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep (2012) 0.82
Identification of cancer stem cell-related microRNAs in hepatocellular carcinoma. Methods Mol Biol (2012) 0.80
Transforming the microenvironment: a trick of the metastatic cancer cell. Cancer Cell (2012) 0.78
Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci (2013) 0.78
Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol (2013) 0.75
At the cancer steering wheel: defining key genomic drivers of liver cancer with next generation sequencing. J Hepatol (2012) 0.75
A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies. Anticancer Res (2007) 0.75